NVS catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 4NCT06501443LATAM LOWERS LDL-CNovartis Pharmaceuticals · HypercholesterolaemiaRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Nov 27, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07517250A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease PatientsNovartis Pharmaceuticals · Familial Mediterranean FeverRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Dec 3, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07465653A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection FractionNovartis Pharmaceuticals · Heart Failure With Reduced Ejection FractionRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Dec 8, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07598448A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in SpainNovartis Pharmaceuticals · Complement 3 GlomerulopathyRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Dec 15, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07786077A Study of Patients' Preferences for Primary Immune Thrombocytopenia TreatmentNovartis Pharmaceuticals · Primary Immune ThrombocytopeniaRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Dec 15, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07626281Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80...Novartis Pharmaceuticals · Inclisiran FormulationRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Dec 21, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07644364HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With HypertensionNovartis Pharmaceuticals · Elevated Blood PressureRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Dec 25, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06684964RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)Novartis Pharmaceuticals · Chronic Myelogenous Leukemia in Chronic PhaseRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Dec 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT05809986Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational StudyNovartis Pharmaceuticals · Relapsing Multiple SclerosisRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06382051Modifying PEST for Psoriatic Arthritis ScreeningNovartis Pharmaceuticals · Plaque PsoriasisRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06905288Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.Novartis Pharmaceuticals · Ankylosing SpondylitisRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07779460A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world PracticeNovartis Pharmaceuticals · Multiple SclerosisRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07683065A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLDNovartis Pharmaceuticals · Plaque PsoriasisRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Jan 15, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT04817618Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.Novartis Pharmaceuticals · C3GRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Jan 29, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07697989Pluvicto Real-world Investigation in Survival in Metastatic CRPCNovartis Pharmaceuticals · Prostatic Neoplasms, Castration-ResistantRecruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Jan 31, 2027Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 15 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.